Gastroparesis and Gastrointestinal Disorders

Gastroparesis is currently a major translational focus of CgA Therapeuticals. Preclinical studies have identified CST and optimized CST derivatives as potential therapeutic candidates for restoring impaired gastric function.

This program is now supported by an NIH/NIDDK SBIR Phase I award (1R43DK148298-01), “Peptide and Peptidomimetic Therapy for Gastroparesis.” The project is advancing CST-based candidates through preclinical efficacy, dose-response, pharmacokinetic, safety, and therapeutic-development studies.

The objective is to identify an optimized CST-based therapeutic candidate capable of providing sustained improvement in gastric function while addressing limitations associated with native peptide stability and duration of action.